Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus.

Journal:

The Journal of infectious diseases, Volume: 231, Issue: 6

Published:

July 11, 2025

PMID:

39960851

Authors:

Felicia C Chow FC, Paddy Kafeero P, Maria Nakimbugwe M, Anthony Ssemaganda A, Colman Tayebwa C, Elana Farrell E, Margaret Wilson M, Payam Nahid P, Rada Savic R, Fiona Cresswell F, Freddie M Kibengo FM

Access Paper

DOI: 10.1093/infdis/jiaf089

PMID: 39960851

Abstract:

Tuberculous meningitis (TBM)-related deaths occur early, often within weeks after treatment initiation. Enhanced treatment early in the disease course with agents that effectively penetrate the central nervous system may improve outcomes in TBM.

Courtesy of the U.S. National Library of Medicine